BERKELEY, Calif., March 7 /PRNewswire/ -- Jivan Biologics Inc., a privately held corporation located in Berkeley, CA, has been awarded US Patent #7,340,349, “Method and System for Identifying Splice Variants of a Gene.” The issued claims cover mathematical algorithms for determining the expression levels of splice isoforms of a gene in a sample using microarrays with exon junction probes.
“The ‘349 Patent validates JIVAN’s position as a leader in the growing market for DNA microarrays to detect alternative splicing,” said Subha Srinivasan, PhD, CEO of JIVAN. “Powerful data analysis is critical to the adoption of splicing arrays, the next generation of expression arrays.”
The ‘349 Patent fits in JIVAN’s broader strategy of providing a complete solution for splice isoform expression, ranging from array design to microarray services to data analysis to PCR validation.
For more information, visit JIVAN at http://www.jivanbio.com.
Jivan Biologics empowers scientists with new insight by providing a full catalogue of splice variant microarrays, analysis software and PCR primer designs to benefit all stages of the drug development pipeline: biomarkers in blood, diagnostics, target validation, toxicology and basic research.
Press contact: Jonathan Bingham, Communications Director, jbingham@jivanbio.com, (415) 425-4115.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: Jonathan Bingham, Communications Director of Jivan Biologics,
Inc. +1-415-425-4115, jbingham@jivanbio.com
Web site: http://www.jivanbio.com/
